We also discovered p21‐activated kinase 1 (PAK1) as a novel downstream effector of cytoplasmic p27‐mediated cell motility that may represent a therapeutic target in OS and other cancers that harbor p27 mislocalization. This evidence concerns the gene CDKN1B and cancer.